122 related articles for article (PubMed ID: 37845178)
1. Discovery of ICOS-Targeted Small Molecules Using Pharmacophore-Based Screening.
Calvo-Barreiro L; Talagayev V; Pach S; Abdel-Rahman SA; Wolber G; Gabr MT
ChemMedChem; 2023 Dec; 18(23):e202300305. PubMed ID: 37845178
[TBL] [Abstract][Full Text] [Related]
2. First-in-class small molecule inhibitors of ICOS/ICOSL interaction as a novel class of immunomodulators.
Abdel-Rahman SA; Ĺwiderek K; Gabr MT
RSC Med Chem; 2023 Sep; 14(9):1767-1777. PubMed ID: 37731692
[TBL] [Abstract][Full Text] [Related]
3. Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies.
Rujas E; Cui H; Sicard T; Semesi A; Julien JP
Nat Commun; 2020 Oct; 11(1):5066. PubMed ID: 33033255
[TBL] [Abstract][Full Text] [Related]
4. AILIM/ICOS: its expression and functional analysis with monoclonal antibodies.
Sakamoto S; Tezuka K; Tsuji T; Hori N; Tamatani T
Hybrid Hybridomics; 2001; 20(5-6):293-303. PubMed ID: 11839247
[TBL] [Abstract][Full Text] [Related]
5. Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple-myeloma microenvironment.
Boggio E; Gigliotti CL; Moia R; Scotta A; Crespi I; Boggione P; De Paoli L; Deambrogi C; Garzaro M; Vidali M; Chiocchetti A; Stoppa I; Rolla R; Dianzani C; Monge C; Clemente N; Gaidano G; Dianzani U
Br J Haematol; 2022 Mar; 196(6):1369-1380. PubMed ID: 34954822
[TBL] [Abstract][Full Text] [Related]
6. ICOS Costimulation Differentially Affects T Cells in Secondary Lymphoid Organs and Inflamed Tissues.
Van DV; Bauer L; Kroczek RA; Hutloff A
Am J Respir Cell Mol Biol; 2018 Oct; 59(4):437-447. PubMed ID: 29676593
[TBL] [Abstract][Full Text] [Related]
7. Design of cyclic peptides as novel inhibitors of ICOS/ICOSL interaction.
Abdel-Rahman SA; Santini BL; Calvo-Barreiro L; Zacharias M; Gabr M
Bioorg Med Chem Lett; 2024 Feb; 99():129599. PubMed ID: 38185345
[TBL] [Abstract][Full Text] [Related]
8. ICOS/ICOSL upregulation mediates inflammatory response and endothelial dysfunction in type 2 diabetes mellitus.
Zhang HY; Ruan LB; Li Y; Yang TR; Liu WJ; Jiang YX; Li TR; Quan J; Xuan W
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8898-8908. PubMed ID: 30575933
[TBL] [Abstract][Full Text] [Related]
9. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy.
Solinas C; Gu-Trantien C; Willard-Gallo K
ESMO Open; 2020 Jan; 5(1):. PubMed ID: 32516116
[TBL] [Abstract][Full Text] [Related]
10. Deep Flow Cytometry Unveils Distinct Immune Cell Subsets in Inducible T Cell Co-Stimulator Ligand (ICOSL)- and ICOS-Knockout Mice during Experimental Autoimmune Encephalomyelitis.
Raineri D; Abreu H; Vilardo B; Kustrimovic N; Venegoni C; Cappellano G; Chiocchetti A
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473756
[TBL] [Abstract][Full Text] [Related]
11. A signaling-enhanced chimeric receptor to activate the ICOS pathway in T cells.
Vettermann C; Victor HP; Sun Y; Plewa C; Gupta S
J Immunol Methods; 2015 Sep; 424():14-9. PubMed ID: 25956037
[TBL] [Abstract][Full Text] [Related]
12. An Antibody Targeting ICOS Increases Intratumoral Cytotoxic to Regulatory T-cell Ratio and Induces Tumor Regression.
Sainson RCA; Thotakura AK; Kosmac M; Borhis G; Parveen N; Kimber R; Carvalho J; Henderson SJ; Pryke KL; Okell T; O'Leary S; Ball S; Van Krinks C; Gamand L; Taggart E; Pring EJ; Ali H; Craig H; Wong VWY; Liang Q; Rowlands RJ; Lecointre M; Campbell J; Kirby I; Melvin D; Germaschewski V; Oelmann E; Quaratino S; McCourt M
Cancer Immunol Res; 2020 Dec; 8(12):1568-1582. PubMed ID: 32999002
[TBL] [Abstract][Full Text] [Related]
13. Multiple combination therapies involving blockade of ICOS/B7RP-1 costimulation facilitate long-term islet allograft survival.
Nanji SA; Hancock WW; Anderson CC; Adams AB; Luo B; Schur CD; Pawlick RL; Wang L; Coyle AJ; Larsen CP; Shapiro AM
Am J Transplant; 2004 Apr; 4(4):526-36. PubMed ID: 15023144
[TBL] [Abstract][Full Text] [Related]
14. Distinct roles of ICOS and CD40L in human T-B cell adhesion and antibody production.
Liu Z; Liu S; Zhang Y; Zeng W; Wang S; Ji P; Pan M; Zhu C; Wang Y
Cell Immunol; 2021 Oct; 368():104420. PubMed ID: 34418679
[TBL] [Abstract][Full Text] [Related]
15. Expression and prognosis of inducible T-cell co-stimulator and its ligand in Chinese stage I-III lung adenocarcinoma patients.
Zhan XK; Liu XK; Zhang S; Chen H
Animal Model Exp Med; 2023 Oct; 6(5):464-473. PubMed ID: 37850501
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of immune-mediated influenza pneumonia by targeting the inducible co-stimulator (ICOS) molecule on T cells.
Sakthivel P; Gereke M; Breithaupt A; Fuchs D; Gigliotti L; Gruber AD; Dianzani U; Bruder D
PLoS One; 2014; 9(7):e100970. PubMed ID: 25029240
[TBL] [Abstract][Full Text] [Related]
17. The role of costimulation in antibody deficiencies: ICOS and common variable immunodeficiency.
Yong PF; Salzer U; Grimbacher B
Immunol Rev; 2009 May; 229(1):101-13. PubMed ID: 19426217
[TBL] [Abstract][Full Text] [Related]
18. Follicular T-helper cell recruitment governed by bystander B cells and ICOS-driven motility.
Xu H; Li X; Liu D; Li J; Zhang X; Chen X; Hou S; Peng L; Xu C; Liu W; Zhang L; Qi H
Nature; 2013 Apr; 496(7446):523-7. PubMed ID: 23619696
[TBL] [Abstract][Full Text] [Related]
19. Inducible T-cell co-stimulator: Signaling mechanisms in T follicular helper cells and beyond.
Panneton V; Chang J; Witalis M; Li J; Suh WK
Immunol Rev; 2019 Sep; 291(1):91-103. PubMed ID: 31402504
[TBL] [Abstract][Full Text] [Related]
20. Inducible Co-Stimulator (ICOS) in transplantation: A review.
Hodgson R; Christiansen D; Ierino F; Sandrin M
Transplant Rev (Orlando); 2022 Dec; 36(4):100713. PubMed ID: 35878486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
